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for a randomized controlled trial
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Abstract
Background: Painful spinal metastases have been treated with conventional radiotherapy for decades, but one-third
of the patients have insufficient pain relief after treatment and one-fifth need retreatment. Stereotactic radiotherapy
is a method to increase the dose in the spinal metastases with a potentially longer lasting palliative effect without
increasing the side effects of the treatment and thereby is expected to improve the quality of life significantly.
Methods/Design: This study is a multicenter prospective randomized clinical trial comparing conventional
radiotherapy (1 x 8Gy) with stereotactic radiotherapy (1 x 20Gy) for pain reduction and quality of life in patients with
painful spinal metastases. A total of 386 patients will be randomized between the two treatment groups. Besides pain
measured by the Dutch Brief Pain Inventory, quality of life and cost-effectiveness also will be measured. The primary
outcome is pain reduction at 6 weeks after treatment. Secondary outcomes will be the time to pain response, duration
of pain relief, health-related quality of life and toxicity, as well as cost-effectiveness.
Discussion: This study investigates whether stereotactic radiotherapy with dose escalation for symptomatic spinal
metastases can lead to improved pain reduction as compared to conventional radiotherapy without an increase of
treatment-related side effects. These results will contribute to the optimization and individualization of the treatment
for the patient.
Trial registration: ClinicalTrials.gov identifier NCT02407795 (March 31, 2015).
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Background
Many patients diagnosed with cancer have already metas-
tasized disease or will metastasize in time. When there are
no curative options, treatment will be focused on main-
taining optimal quality of life. Up to 70 % of all bony
metastases are located in the spinal column. Spinal verte-
bral metastases can give serious pain complaints, which
are likely to progress in time and thereby decrease the
quality of life [1]. Besides pain or risk of fracture, these
metastases may also lead to spinal cord compression. Of
all patients with spinal metastases, 8 to 20 % will develop
symptomatic spinal cord compression, which, untreated,
will lead to neurological complications such as the inabil-
ity to walk or stand.
Conventional radiotherapy has been used for decades
for palliation of pain caused by bone metastases. Patients
are treated in a single or multiple fractions. Generally, a
reduction in pain will occur in two-thirds of patients
within 4 to 6 weeks after irradiation. Retreatment is ne-
cessary in up to 24 % of all patients [2]. Various studies,
randomized or retrospective, have focused on dose and
fractionation schemes in an effort to increase the efficacy
of radiotherapy. The majority of these studies found no
evidence that a single dose of 8Gy was inferior in pain
relief compared to fractionated schedules for a higher
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irradiation dose, although the incidence of re-irradiation
was higher using a single dose [2–7]. Because of these
studies, in the Netherlands, a single dose of 8Gy is
mainly used for painful metastatic lesions. In recent
years, the results of systemic therapies improved signifi-
cantly resulting in a better median survival of patients
with metastatic disease. Therefore, patients nowadays
that are irradiated to a single dose of 8Gy for spinal ver-
tebral metastases are at higher risk of relapsing at the ir-
radiated site. Re-irradiation can be offered to the patient;
however, with conventional treatment, the radiation dose
that can be given may be limited by the tolerance of the
spinal cord.
Stereotactic body radiotherapy (SBRT) allows dose es-
calation to the spinal vertebra or paraspinal tumor with
steep dose gradients that limit exposure to the spinal
cord and other organs at risk. As the dose to the non-
involved organs at risk is strongly reduced, fewer side ef-
fects will be expected compared to conventional radio-
therapy. Due to the biologically higher dose that can be
given to the target volume compared to conventional
radiotherapy, better results are anticipated, especially
when more radio-resistant tumors like renal carcinoma
or melanoma are treated. Another question to be an-
swered is whether we can identify a subgroup of patients
that will benefit more from high dose stereotactic irradi-
ation as compared to the conventionally used single
fraction of 8Gy radiotherapy.
No data are available from randomized clinical trials
comparing the standard 8Gy to SBRT high dose, nor are
there dedicated phase I dose escalation studies. The total
dose and the fractionation schemes have been mainly
dependent on the physician [8–10]. The first patients
treated by stereotactic radiotherapy for spinal metastases
were reported in 1995. These patients were treated with
multiple fractions. As time, and therefore experience,
progressed, treatment techniques improved, and the
number of indications for stereotactic radiotherapy in-
creased. Currently, SBRT is a proven successful treat-
ment modality for brain, liver, and lung tumors, as well
as metastatic disease to these organs. Currently, one
other active randomized trial in the United States is in-
vestigating single fraction conventional versus stereotac-
tic radiotherapy for spinal metastases (RTOG 0631). In
that trial, a single fraction of radiotherapy with conven-
tional 8Gy is compared to stereotactic 16Gy, with pri-
mary endpoint pain relief at 3 months after treatment.
Unfortunately, no time to response is measured, no con-
sensus delineation rules have to be used, and no stan-
dardized quality of life questionnaires are used. Finally, if
the trial is negative, it may be disputed whether 16Gy is
sufficiently higher relative to 8Gy for obtaining a signifi-
cant improvement in pain relief. Institutions already treat-
ing patients with stereotactic radiotherapy have reported
doses of 20 to 24Gy as being a standard treatment, with-
out serious toxicity [11]. However, when patients have
been treated with a single fraction dose > 20Gy, an in-
creased risk for vertebral compression fracture has been
reported, especially in patients with baseline compression
fractures, lytic tumors, or spinal misalignment [12, 13].
The aim of this study is to investigate whether stereo-
tactic radiotherapy for symptomatic spinal metastases
can lead to improved pain reduction as compared to
conventional radiotherapy, without an increase of treat-
ment related side effects and thereby result in a better
quality of life. The primary objective is pain reduction,
but we also focus on the duration of pain relief as an im-
portant secondary endpoint besides quality of life and
cost-effectiveness. To answer these questions, an inten-
sive scheme of time points for questionnaires and pain
scores will be used. These results will contribute to the
optimization and individualization of the treatment for
the patient.
Methods/Design
This is a multicenter, prospective randomized clinical trial
to investigate pain reduction after radiotherapy. Two dif-
ferent radiation doses will be evaluated: 1 x 20Gy by SBRT
and 1 x 8Gy conventional radiotherapy.
Objectives/endpoints
The primary objective is to investigate whether stereotactic
radiotherapy for symptomatic spinal metastases can lead to
improved pain reduction as compared to conventional
radiotherapy without an increase of treatment-related side
effects. The primary endpoint will be pain reduction after
treatment. Secondary endpoints are time to pain response,
duration of pain relief, quality of life, and toxicity. In
addition, cost-effectiveness will be studied.
Recruitment and randomization
Patients must be able to undergo radiotherapy and fulfill
the eligibility criteria. The diagnosis of a solid tumor
must be pathologically confirmed to make the patient
eligible for the study. The extent of the metastases in the
spine should be visualized on an MRI, no longer than
two weeks before randomization or no longer than
6 weeks before the start of treatment. To determine the
clinically relevant category of stability, the Spinal In-
stability Neoplastic Score (SINS) will be obtained and
documented prior to treatment. Earlier studies showed
that the sensitivity of SINS for potentially unstable or
unstable lesions was 95.7 %, with a specificity of 79.5 %
[14, 15]. Written informed consent will be obtained from
all participants before entering the study.
The study is designed to be carried out in multiple cen-
ters in the Netherlands. Patient randomization will only
be allowed from authorized investigators, their authorized
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staff members, or data manager. A patient can be random-
ized only after verification of eligibility. In case a patient is
eligible and a written informed consent is obtained, the
randomization form must be faxed or digitally sent to the
Data Center. Randomization will be performed using a
password-protected database (OpenClinica). Patients will
be stratified on primary tumor type (breast/prostate, non-
small-cell lung/renal/colorectal/sarcoma/melanoma and
others), Karnofsky performance status (60 to 70 versus 80
to 100) and number of spinal metastases (single lesion, 2
to 3 lesions, and disseminated osseous lesions).
Inclusion and exclusion criteria
Inclusion criteria are as follows:
1. Histologically proven solid tumor with radiological
diagnosis of spinal metastases
2. Pain score minimum 2 on an 11-point scale (0 = no
pain to 10 = worst imaginable pain)
3. Maximum of two consecutive or noncontiguous
spinal segments involved by tumor at current level
of interest
4. Gross tumor optimally > 3 mm from the spinal cord
on MRI
5. Karnofsky performance status ≥ 60
6. WHO 0-1-2
7. Life expectancy > 6 weeks
8. Age ≥ 18 years
9. Nonpregnant, nonlactating female patients. Sexually
active patients of childbearing potential must
implement effective contraceptive practices during
the study
10.Written informed consent
Exclusion criteria are as follows:
1. History of previous radiotherapy to the spine at the
current level of interest or overlapping location
2. Chemotherapy or targeted systemic therapy within
14 days of radiotherapy
3. Spinal instability or neurological deficit resulting
from bony compression of neural structures
4. Pathologic fracture or impending fracture needing
surgical fixation
5. Prior surgery to the spine at the current level of
interest or overlapping location
6. Gross tumor < 3 mm from the spinal cord on MRI
7. More than 25 % spinal canal compromise
8. Patients with a pacemaker such that MRI cannot be
performed or the treatment cannot be delivered
safely
9. Patients not able to undergo MRI
10.Earlier nuclear medicine treatment for example
strontium 89 treatment
11.Pregnancy
12.Altered mental status that would prohibit the
understanding and giving of informed consent
Assessment of the endpoints
Time to response is calculated from the date of
randomization. Pain is self-reported by the patient and
will be measured by an adjusted version for daily use of
the Dutch Brief Pain Inventory (BPI). The BPI assesses
pain on a 0–10 scale, where 0 is no pain and 10 is worst
imaginable pain. It also has a questionnaire that con-
sists of questions on severity of pain, impact of pain on
daily function, location of pain, pain medications, and
amount of pain relief in the past 24 hours or the past
week. It is a short questionnaire that requires 5 minutes
to complete. The BPI has been validated in more than
25 different languages. Response to treatment is calcu-
lated taking into account changes in the administration
of opioids. Quality of life will be assessed using the
EORTC QLQ-C15-PAL and the EORTC QLQ-BM22
[16–18]. These are well-validated, quality-of-life instru-
ments specific to bone metastases. The EORTC QLQ-
C15-PAL is a shortened version of the EORTC-C30,
which is one of the most widely used questionnaires.
The QLQ-C15-PAL consists of 15 items, and is the core
questionnaire for palliative care. The QLQ-C15-PAL is
supplemented by the disease specific module: the EORTC
QLQ-BM22. This module is developed specifically for pa-
tients with bone metastases to evaluate the benefits and
side effect of a treatment. It is intended to supplement the
core questionnaire QLQ-C15-PAL and has completed all
phases of testing as a reliable, validated, cross-cultural ap-
plicable module. The QLQ-BM22 contains 22 items di-
vided into four scales assessing painful sites (five items),
painful characteristics (three items), functional interfer-
ence (eight items), and psychosocial aspects (six items).
Both the QLQ-C15-PAL and the QLQ-BM22 question-
naires are patient rated because the gold standard for
assessing symptom experience is self-reporting by the
patient. The questionnaires will be available on paper or
electronically, according to the wish of the patient. Tox-
icity is assessed using the CTC-AE 4.0. To measure the
quality of the health status of the patients, the EuroQol-
5D will be used [19]. In both randomization arms, the pa-
tients will be asked to fill out the following:
1. Days 0 to 14: their daily average, worst and present
pain, intake of medication (dosage), and effect of
medication (BPI)
2. Days 0, 7, and 14: effect of their pain on quality of
life items (general activity, mood, walking ability,
normal work, relations with other people, sleeping,
enjoyment of life, and overall quality of life
(EORTC-QOL)
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3. Weeks 4 and 6 and months 2, 3, 4, 6, 9, 12, and
thereafter, every 6 months with a maximum of
5 years or until death, both the BPI and QOL
questionnaires. Concomitant use of analgesics
should be noted.
Post-treatment diagnostics should be performed accord-
ing to the institutions routine guidelines. Recurrence of
disease should preferably be confirmed using MRI. Tumor
growth less than 25 % is classified as stable disease. Data
needed for re-irradiation and the occurrence of spinal
cord compression and/or fractures, along with data on
systemic treatment are collected at 3-month intervals at
the institutes.
The pain score will be divided into four response cat-
egories for analyses. Complete response (CR) is defined
as a pain score of 0 at the treated site, with no concomi-
tant increase in analgesic intake. Partial response (PR) is
defined as a pain reduction of 2 or more at the treated
side on a scale of 0 to 10 without analgesic increase, or
an analgesic reduction of 25 % or more from baseline
without an increase in pain. Pain progression (PP) is de-
fined as an increase in pain score of 2 or more above
baseline at the treated site with stable analgesic intake or
an increase of 25 % or more in analgesic intake com-
pared with baseline with the pain score stable or 1 point
above baseline. Stable pain (SP) is defined as any response
that is not captured by the complete response, partial re-
sponse, or pain progression definitions. Responders are
defined as CR + PR; nonresponders are defined as PP + SP.
Radiotherapy
For conventional radiotherapy, a single dose of 8Gy will
be given using a linear accelerator with at least 6 MV
photons. Preferably patients are treated using the ICRU
guidelines, but there are no restrictions formulated with
respect to the radiation technique. Patients should be
treated according to the standard treatment protocol per
institution.
For stereotactic treatment (1 x 20Gy), patients will be
prepared with a dedicated CT simulator in treatment
position with an immobilization device as used per in-
stitution. Standard position is supine, no prone position
is allowed. Scans should be matched with the pretreat-
ment (diagnostic) MRI images as they provide better
delineation of the tumor and the spinal cord than the
simulator CT scan. Target volumes are defined according
to the ICRU Reports 50 and 62 and according to the Inter-
national Spine Radiosurgery Consortium Consensus
Guidelines for Target Volume Definition in Spinal Stereo-
tactic Radiosurgery [20]. Dose-volume-histograms of the
spinal cord or cauda equine, as well as from the organs at
risk in the vicinity, will be obtained for all patients. For the
spinal cord a maximum of 10Gy to 10 % of the spinal cord
volume, which is defined as 6 mm above and below the
target volume, is tolerated [21]. Circumferential radiation
of the esophagus, trachea, great vessels, stomach, bowel,
and rectum should be avoided. Patients should not receive
chemotherapy or targeted systemic therapy within 14 days
of radiotherapy. All palliative therapy and supportive care
for disease-related symptoms will be offered to all patients
on this trial. Details of these will be collected on case re-
ports forms. Patients who do not achieve a response to
radiotherapy, re-irradiation should only be considered
4 weeks after the initial treatment and only for the con-
ventionally (8Gy) treated patients.
Statistical analyses
The primary outcome of interest in this study is a reduc-
tion of pain of 2 points at 6 weeks since baseline. The
literature shows that in patients with conventional radio-
therapy the percentage of patients with pain reduction
ranges from 66 % to 72 %. We assume that the percent-
age of patients with pain reduction is 70 % in the group
with conventional radiotherapy compared to 85 % in the
group with stereotactic radiotherapy. Therefore, 135 pa-
tients are needed in each group to obtain a power of 80 %
(Fisher-exact test, two-sided, alpha = 0.05). We adjust for a
drop-out rate of 30 % and will include a total of 386 pa-
tients. The primary analysis will be the comparison be-
tween the two treatment arms of the proportion of
patients with pain reduction, defined as a decrease in pain
score of at least 2 points from initial pain score, at 6 weeks.
Time to pain progression, radiation-induced fracture and/
or death will be calculated from date of randomization to
the documentation. For the calculation of response, no
fixed time interval from the date of randomization will be
applied. Response of treatment will be calculated if at least
two successive follow-up pain scores are available.
Ethical issues, information, and safety
The protocol has been written and will be conducted ac-
cording to the ICH Harmonized Tripartite Guideline for
Good Clinical Practice. The study protocol was approved
by the Central Dutch Medical Ethical Committee of the
Radboud University Medical Center Nijmegen (2014).
The regulations regarding medical confidentiality and
data protection are fulfilled.
Discussion
The aim of this trial is to test the hypothesis that stereo-
tactic radiotherapy gives a better and longer lasting reduc-
tion of pain, better local control, and therefore a better
quality of life without an increase of treatment-related side
effects compared to conventional radiotherapy for symp-
tomatic spinal metastases. Recent trials and reports using
SBRT show excellent local control and a fast pain reduc-
tion in 1 to 2 weeks when treating painful spinal
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metastases [8, 10, 11, 22–26]. In recent years, systemic
therapies have improved significantly, resulting in a better
median survival of incurable patients, that is, with metas-
tasized disease. Therefore, patients nowadays that are irra-
diated conventionally for spinal vertebral metastases are at
a higher risk of local recurrence. The question is
whether the conventional treatment is still appropriate
for patients with potentially longer life expectancy, for
example, patients with oligometastases or patients with
tumors responsive to systemic treatments. Oligometas-
tasis is defined as the state in which the patient shows
distant relapse in only a limited number of regions. For
these patients, a more radical approach could have a
major impact on their quality of life and even life ex-
pectancy. In addition, stereotactic treatment shows a
faster reduction of pain, occurring within 1 to 2 weeks,
compared to pain reduction from conventional treat-
ment, which usually occurs in 4 to 6 weeks. Therefore,
patients with short life expectancies may also benefit
from stereotactic treatment.
Quality of life is an important issue in cancer patients
at all stages of disease. Quality of life is affected by many
factors such as the disease itself, but also psychological
and social factors. In patients with pain, the quality of
life can be impaired due to the pain or the disease itself
but also by the multiple treatments to which patients are
exposed. The minimization of hospital visits is import-
ant. Furthermore, the analgesics can give side effects that
may have a negative impact on the quality of life. Radio-
therapy can reduce pain resulting from bone metastases
and reduce analgesic use and it side effect, thereby im-
proving the quality of life [1]. Knowledge of health-
related quality of life and its implementation in the treat-
ment options can help to guide patients in making deci-
sions and personalize their treatment.
The question to be answered is whether we can iden-
tify a subgroup of patients that will benefit from a high
dose stereotactic irradiation and consequently have a
better quality of life as compared to the frequently used
single fraction of low-dose conventional radiotherapy.
This in order to optimize and to individualize the treat-
ment options for the patient.
Trial status
This trial began in May 2015 and is currently recruiting.
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